CytoDyn Inc.

CytoDyn Inc. is a clinical-stage biotechnology company headquartered in Vancouver, Washington, focused on the development of innovative treatments. The company's mission is to enhance the lives of patients through target-specific medicine and therapeutic innovation, addressing significant unmet medical needs.

CytoDyn's core product candidate is leronlimab (also known as PRO 140), a novel humanized monoclonal antibody that acts as a C-C chemokine receptor type 5 (CCR5) antagonist. The CCR5 receptor, found on immune and cancer cells, is implicated in various disease processes, including cancer metastasis, infectious diseases, and autoimmune conditions. The company's pipeline primarily targets solid-tumor oncology, with ongoing clinical development in metastatic triple-negative breast cancer (mTNBC) and metastatic colorectal cancer (mCRC). CytoDyn also explores leronlimab's potential in inflammatory diseases, autoimmune conditions, and metabolic dysfunction-associated steatohepatitis (MASH).

Recent developments include the appointment of Dr. Jacob Lalezari as CEO in January 2024 and Robert E. Hoffman as CFO in May 2025. In April 2026, CytoDyn announced the dosing of the first patient in an Expanded Access Program for leronlimab in triple-negative breast cancer and presented new data for leronlimab in metastatic colorectal cancer at the AACR Annual Meeting. The company also completed enrollment in its Phase 2 metastatic colorectal cancer study in April 2026 and secured $17.5 million in financing in March 2026 to support ongoing clinical development.